Skip to main content
. 2011 Jan;132(1):144–154. doi: 10.1111/j.1365-2567.2010.03349.x

Figure 6.

Figure 6

Effects of in vivo treatment with anti-CCR3 monoclonal antibody. Effect of in vivo treatment with the anti-CCR3 monoclonal antibody versus its isotype control (rat IgG2b) antibody, on (a) bronchoalveolar lavage (BAL) CD34+, (b) BAL CD34+ Sca1+ cells and (c) bone marrow (BM) CD34+ cells in ovalbumin (OVA) -sensitized/exposed BALB/c mice. The antibody was administered intraperitoneally (30–300 μg) 1 hr before exposure on the first day of exposure. Data are shown as mean (+ SEM) (n = 6–9). *P< 0·05 compared with the rat IgG2b-treated group.